Growth Hormone Secretagogue Research Peptides Explained: Sermorelin, Ipamorelin, CJC-1295 and Tesamorelin

For laboratory and research use only. The information below is provided strictly for educational and scientific reference. This compound is not intended for human consumption, diagnosis, or treatment.

Growth hormone secretagogues are one of the most studied families in the peptide literature, and one of the most frequently misunderstood by newcomers to laboratory procurement. The category covers several structurally distinct molecules that converge on the same axis — the hypothalamic–pituitary signalling pathway that governs endogenous growth hormone release. For researchers sourcing compounds in the Philippines, understanding how these peptides differ at the receptor level is the difference between a coherent study design and an expensive shelf of redundant vials.

What "growth hormone secretagogue" actually describes

The term covers any compound that stimulates the pituitary to release growth hormone rather than supplying growth hormone directly. In the published literature these divide into two broad mechanistic classes:

• GHRH analogues — molecules modelled on growth hormone-releasing hormone, which bind the GHRH receptor on somatotroph cells. Sermorelin, CJC-1295 and Tesamorelin belong here.
• Ghrelin receptor agonists (GHRPs) — molecules acting at the growth hormone secretagogue receptor (GHS-R1a), a separate target with a different downstream signalling profile. Ipamorelin is the best-characterised example in this class.

Because the two classes act on different receptors, laboratory studies frequently examine them in parallel or in combination to model additive versus synergistic signalling. That experimental logic is why blended preparations exist in the research supply market at all.

Sermorelin: the reference GHRH fragment

Sermorelin is a 29-amino-acid fragment corresponding to the biologically active N-terminal region of endogenous GHRH. It is the shortest sequence that retains full receptor activity, which makes it a useful baseline comparator in receptor-binding and pituitary-response studies. Its defining characteristic in the literature is a short plasma half-life — typically reported in minutes — which produces a sharp, pulsatile signal rather than sustained receptor occupancy. Research groups modelling physiological pulsatility often select Sermorelin research peptide precisely for that rapid clearance profile.

CJC-1295: extending the GHRH signal

CJC-1295 is a modified GHRH analogue in which four amino acid substitutions confer resistance to enzymatic degradation by dipeptidyl peptidase-4. The version most commonly used in laboratory work is the "No DAC" form — that is, without the Drug Affinity Complex moiety that, in the DAC-bearing variant, binds serum albumin and dramatically extends circulating duration. The No DAC form is sometimes referred to in older literature as Modified GRF (1-29).

The practical consequence for study design is duration of action. CJC-1295 (No DAC) research peptide offers a longer signalling window than Sermorelin while still clearing on a timescale that allows pulsatile modelling. Researchers comparing short- versus extended-duration GHRH receptor engagement typically run both compounds against a shared control.

Ipamorelin and the ghrelin receptor pathway

Ipamorelin is a pentapeptide GHS-R1a agonist notable in the literature for receptor selectivity. Earlier-generation growth hormone-releasing peptides showed measurable cross-activity at other endocrine pathways in preclinical models; Ipamorelin was developed specifically to minimise that cross-talk, which is why it appears so frequently as the GHRP arm in comparative studies. Ipamorelin research peptide is generally the cleanest available tool for isolating ghrelin-receptor-mediated effects from GHRH-receptor effects.

Why combination preparations appear in research catalogues

Because GHRH analogues and ghrelin receptor agonists act at separate receptors, a considerable body of preclinical work examines whether co-administration produces an effect greater than the sum of the two pathways acting alone. Combination research preparations such as the CJC-1295 + Ipamorelin blend research peptide exist to support that experimental question in a single reconstitution, reducing the handling variables introduced when two separately reconstituted vials are combined at the bench.

A fourth compound, Tesamorelin research peptide, is a stabilised GHRH analogue distinguished by a trans-3-hexenoyl modification at the N-terminus. It occupies a slightly different niche in the literature, with the bulk of published work focused on adipose tissue and metabolic endpoints rather than general somatotroph signalling.

Laboratory handling considerations across the category

These peptides share the handling profile common to small lyophilised sequences. Key points that recur across the category:

• Lyophilised powder is stable at refrigerated temperatures; reconstituted solution has a substantially shorter usable window and should be kept cold and protected from light.
• Repeated freeze–thaw cycling is the most common avoidable cause of measurable potency loss in comparative assays. Aliquoting after reconstitution avoids it.
• Solvent choice affects solution stability. Most of these sequences reconstitute cleanly in bacteriostatic water; researchers running extended timepoints should consult the compound-specific documentation before selecting a solvent.
• Because half-lives across this category differ by orders of magnitude, timepoint selection matters more here than in most peptide families. Sampling schedules built for one compound rarely transfer directly to another.

Researchers assembling a comparative panel across this pathway can browse the full range of research peptides to see available formats, vial sizes and third-party testing documentation.

Reading the category as a whole

Viewed together, these four compounds form a usable gradient rather than a set of interchangeable options: a short-acting GHRH reference (Sermorelin), an extended GHRH analogue (CJC-1295 No DAC), a selective ghrelin receptor agonist (Ipamorelin), and a structurally stabilised GHRH analogue with a distinct metabolic literature (Tesamorelin). Selecting between them is a question of which receptor and which signalling duration the study is designed to interrogate — not a question of which is strongest.

Products are sold strictly for laboratory research and are not for human or animal consumption.